Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 positive
Therapy Pembrolizumab
Indication/Tumor Type Hodgkin's lymphoma
Response Type predicted - sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive Hodgkin's lymphoma predicted - sensitive Pembrolizumab Phase Ib/II Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 60.0% (9/15, 2 complete response, 7 partial response) and a disease control rate of 80.0% in pediatric patients with CD274 (PD-L1)-positive Hodgkin's lymphoma, with a median progression-free survival of 12.2 months (PMID: 31812554; NCT02332668). 31812554
PubMed Id Reference Title Details
(31812554) Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Full reference...